According to a recent LinkedIn post from Daymark Health, the company is marking one year since treating its first patient under a value-based, home-centered cancer care model. The post cites more than 1,400 in-home appointments, 4,500 phone and video visits, and 70,000 total patient touchpoints, framing the period as proof of concept for its approach.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests that Daymark’s first year focused on demonstrating that proactive, coordinated, and accountable cancer care can be delivered outside traditional, fee-for-service structures. It further indicates that the company now aims to scale this model in its second year, which could imply increased investment needs but also potential revenue growth if payer and provider demand for value-based oncology solutions continues to develop.
The emphasis on payers, providers, and ecosystem partners being “hungry” for new models hints at a strategy centered on contracting and collaboration with insurers and health systems. For investors, this points to a business model tied to value-based reimbursement arrangements, where financial performance will likely depend on Daymark’s ability to expand coverage contracts, demonstrate cost savings, and maintain quality outcomes at scale.
The post highlights internal investment in the team and operations, suggesting continued spending on clinical capacity and care coordination infrastructure. If successful, scaling the “magic” referenced in the post could enhance Daymark’s competitive position in the emerging value-based cancer care segment, but it also underscores execution risk as the company transitions from pilot-scale operations to broader deployment.